Drugs / Famotidine
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | PEPCID AC | — | 1998-11-09 – 2007-12-17 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | PEPCID | — | 1988-10-17 – 2002-06-06 | fda.gov ↗ |
| Approved | US (FDA) | PEPCID | — | 1986-10-15 | fda.gov ↗ |
Trials 60 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 125 trials | ||||||
| Phase 1 | NCT07018635 | Jul → Sep 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06170723 | Mar → May 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06213818 | Mar 2024 → Aug 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06054464 | Sep → Nov 2023 | — | PMV Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05866627 | Jul → Sep 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04935112 | Jul → Aug 2021 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04941755 | Jun → Sep 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04903093 | Jun → Oct 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04545008 | Oct 2020 → Jun 2021 | COVID-19 | Prisma Health-Upstate | Terminated | No outcome recorded |
| Phase 1 | NCT04540965 | Sep → Dec 2020 | — | Calithera Biosciences, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04453189 | Jul → Sep 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04470778 | Jul 2020 → Mar 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05599828 | Jul → Sep 2020 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04390334 | May → Jun 2020 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04179071 | Dec 2019 → Mar 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03451110 | Feb → Mar 2018 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03302845 | Sep → Oct 2017 | — | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02097329 | Apr → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01841489 | May → Aug 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01734759 | Nov 2012 → Jan 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01000818 | Jun 2008 → Mar 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00451880 | Feb 2007 → Oct 2011 | colorectal cancer, melanoma, non-small cell lung carcinoma, thyroid gland papillary carcinoma | Exelixis | Completed | No outcome recorded |
| Phase 1 | NCT00422097 | Jan 2007 → Aug 2009 | cancer | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT00365339 | Apr → Jun 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01511731 | Oct 1998 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05085574 | Feb 2023 | COVID-19 | Leidos Life Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT05077332 | Dec 2021 → Nov 2025 | COVID-19 | Leidos Life Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05077969 | Dec 2021 → Jun 2022 | COVID-19 | Leidos Life Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04248712 | Jul 2020 → Dec 2021 | eosinophilic esophagitis | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT03554291 | May 2019 → Jul 2023 | heart failure, pulmonary arterial hypertension | University of Washington | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05084521 | Jan → Dec 2022 | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT01946295 | Mar 2014 → Aug 2016 | schizophrenia | Jesper Ekelund | Unknown | No outcome recorded |
| Phase 2/3 | NCT00141960 | Sep 2005 → ? | gastroesophageal reflux disease | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT06801626 | Mar 2025 → Dec 2026 expected | — | The University of Texas Medical Branch, Galveston | Recruiting | No outcome recorded |
| Phase 3 | NCT05946551 | Mar → Jun 2024 | COVID-19 | Emory University | Terminated | No outcome recorded |
| Phase 3 | NCT04504240 | Aug 2020 → Apr 2021 | COVID-19 | Chattogram General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00984815 | Sep 2009 → Jul 2011 | complex regional pain syndrome, osteoarthritis, rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00613106 | Sep 2007 → Oct 2008 | complex regional pain syndrome, osteoarthritis, rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00450216 | Mar 2007 → Aug 2008 | ulcer disease | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00450658 | Mar 2007 → Sep 2008 | peptic ulcer disease | Amgen | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT05455359 | Feb 2025 → May 2027 expected | aspiration pneumonia, dyskinesia of esophagus, functional gastric disease, gastroesophageal reflux disease | Boston Children's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04836806 | Aug 2021 → Jul 2022 | COVID-19 | Emory University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04565392 | May → Nov 2021 | COVID-19 | drpykessupplements.com | Withdrawn | No outcome recorded |
| Phase 4 | NCT01563185 | Apr 2012 → Mar 2015 | juvenile idiopathic arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT02703896 | Jan 2012 | lung disorder | King Saud University | Completed | No outcome recorded |
| Phase 4 | NCT01232127 | Feb → Jun 2011 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00950339 | Aug 2009 → Jun 2011 | coronary artery disorder | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00565175 | Jan 2008 → Dec 2011 | schizophrenia | Jesper Ekelund | Completed | No outcome recorded |
| Phase 4 | NCT00384904 | Dec 2006 → Dec 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT01928888 | May 2003 → Feb 2004 | dyspepsia | Bayer | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07539961 | Sep 2026 → Dec 2027 expected | calcific tendinitis | University Hospital Dubrava | Not yet recruiting | No outcome recorded |
| — | NCT06629337 | Apr → Aug 2024 | hypertensive disorder | California Baptist University | Completed | No outcome recorded |
| — | NCT06313307 | Apr → Nov 2023 | hyperpigmentation of the skin | Second Affiliated Hospital of Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT05131555 | Aug → Dec 2021 | — | University Ghent | Completed | No outcome recorded |
| — | NCT04123899 | Oct → Nov 2019 | peptic ulcer disease | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04450134 | Oct → Dec 2019 | — | University Ghent | Completed | No outcome recorded |
| — | NCT02551744 | Jul 2012 → Jul 2018 | peptic ulcer disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01079052 | Nov 2007 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
| — | NCT01079065 | Nov 2007 | — | Ranbaxy Laboratories Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 65 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 119 trials | ||||||
| Phase 1 | NCT07629999 Background | Jun 2026 → Jun 2027 expected | — | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07171619 Comparator | Aug → Nov 2025 | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT06789172 Background | Jan 2025 → Jul 2028 expected | colorectal cancer, dedifferentiated liposarcoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma +6 | Epkin | Recruiting | No outcome recorded |
| Phase 1 | NCT06332638 Comparator | Mar → Jul 2024 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT06144697 Background | Jan → Oct 2024 | — | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT05035407 Background | Mar 2022 → Jul 2025 | — | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT04949269 Background | Jul 2021 → Jan 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04840615 Background | Jun → Dec 2021 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT04550195 Background | Sep 2020 → Mar 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04536961 Background | Sep → Dec 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04209699 Background | Dec 2019 → Feb 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04175925 Background | Nov 2019 → Jul 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03805932 Background | Oct 2019 → Jul 2023 overdue | hairy cell leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04065932 Background | Aug → Dec 2019 | lupus erythematosus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03330028 Background | Oct 2017 → Apr 2023 | upper digestive tract disorder | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03142165 Background | May → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02763969 Background | May → Dec 2016 | psoriasis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02684799 Comparator | Jan → Apr 2016 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02534636 Background | Oct 2015 → Nov 2016 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06481306 Background | Jul 2024 → Apr 2028 expected | sickle cell disease | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06265077 Comparator | Feb → Oct 2024 | breast cancer | Noha Mansour | Completed | No outcome recorded |
| Phase 1/2 | NCT06207305 Background | Jan 2024 → Jan 2028 expected | appendix adenocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04990388 Background | Oct 2021 → Mar 2023 | glycogen storage disease III | Ultragenyx Pharmaceutical Inc | Terminated | No outcome recorded |
| Phase 1/2 | NCT04614974 Comparator | Nov 2020 → May 2024 | gastroesophageal reflux disease, laryngeal disorder | Reema Padia | Terminated | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT06819670 Comparator | May 2025 → Feb 2028 expected | infantile spasms | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT06706258 Comparator | Jan 2025 → Dec 2026 expected | acute kidney injury | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT06154226 Comparator | Jan → Sep 2024 | acute kidney injury | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT05977998 Background | Sep 2023 → Oct 2028 expected | gastric adenocarcinoma, metastatic carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04918147 Background | Oct 2021 → Jan 2024 | immunoglobulin G4-related sclerosing disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04724720 Comparator | Jan → May 2021 | COVID-19 | Northwell Health | Completed | No outcome recorded |
| Phase 2 | NCT04621149 Comparator | Nov 2020 → Mar 2022 | COVID-19 | Profact, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04308837 Background | Dec 2018 → Aug 2025 | gastric cancer | Icahn School of Medicine at Mount Sinai | Unknown | No outcome recorded |
| Phase 2 | NCT03107182 Background | Jun 2017 → Sep 2024 | head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT02142712 Background | Dec 2014 | brain edema, stroke disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT01937078 Comparator | Apr 2011 → Mar 2014 | movement disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04862585 Comparator | Oct 2021 → Jun 2024 | breast carcinoma in situ, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT05043350 Background | Sep 2021 → Jul 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05965492 Background | Jun 2024 → Jun 2025 | spinal cord disorder | University of Miami | Withdrawn | No outcome recorded |
| Phase 3 | NCT05024721 Comparator | Aug 2021 → Mar 2022 | gastritis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT04340297 Background | Jun 2020 → Dec 2021 | gastroesophageal reflux disease | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT04370262 Comparator | Apr → Sep 2020 | COVID-19 | Northwell Health | Completed | No outcome recorded |
| Phase 3 | NCT03647072 Comparator | Aug 2018 → Oct 2027 expected | lymphoma | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT01499368 Comparator | Nov 2011 → Nov 2012 | esophagitis | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01408186 Comparator | Jan 2011 → Nov 2015 | peptic ulcer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00229424 Comparator | Apr 2005 → Oct 2006 | gastroesophageal reflux disease | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT07101445 Background | Sep 2025 → Dec 2026 expected | plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
| Phase 4 | NCT06743243 Comparator | Jul 2025 → Oct 2026 expected | — | Seok Kyeong Oh | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06241183 Comparator | Nov 2023 → Dec 2027 expected | dyspepsia, gastroesophageal reflux disease | Stony Brook University | Recruiting | No outcome recorded |
| Phase 4 | NCT04990804 Background | Aug 2021 → Feb 2022 | spinal cord disorder, substance-related disorder | Vanderbilt University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT04766996 Background | May → Dec 2021 | substance-related disorder | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT03667703 Comparator | Mar 2019 → Jun 2022 | congenital heart disease, infectious disease, peptic ulcer disease | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01180179 Comparator | Jun 2010 → May 2019 | peptic ulcer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01062516 Comparator | Jan → Sep 2010 | acute coronary syndrome, acute myocardial infarction | Ruttonjee Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00978159 Comparator | Sep 2009 → Dec 2013 | dyspepsia | Ruttonjee Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00683111 Comparator | Jul 2008 → Dec 2011 | acute coronary syndrome, acute myocardial infarction | Ruttonjee Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00839488 Comparator | Apr 2008 → Mar 2009 | gastric ulcer | Far Eastern Memorial Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00633035 Comparator | Sep 2007 → Mar 2010 | ulcer disease | Far Eastern Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00557349 Comparator | Nov 2006 → Nov 2007 | ulcer disease | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 4 | NCT00843063 Comparator | Aug 2004 → Dec 2008 | peptic ulcer disease | Ruttonjee Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06211088 Comparator | Aug → Dec 2024 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT04463420 Background | Aug → Nov 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Unknown | No outcome recorded |
| — | NCT02473042 Background | Mar 2016 → Nov 2024 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT02700087 Comparator | Feb 2016 → Feb 2017 | gastroesophageal reflux disease, laryngeal disorder | Stanford University | Withdrawn | No outcome recorded |
| — | NCT02410460 Background | Sep 2013 → Jun 2014 | — | Mercy Facial Plastic Surgery Center | Completed | No outcome recorded |
| — | NCT02418312 Comparator | Jan 2012 → Oct 2017 | peptic ulcer disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2001-05-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Famotidine Tablets,10mg tevapharm.com ↗ |
| 2001-04-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Famotidine 20 & 40mg tevapharm.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 126 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Famotidine | “HZT-501, a fixed-dose combination of ibuprofen, a pain and inflammation relieving non-steroidal anti-inflammatory drug (NSAID), and famotidine, a histamine type 2 receptor...” NCT00984815 ↗122“The subject should maintain a minimum of 10 hours of empty stomach before administration, and swallow an oral dose of 1 tablets (Famotidine 20 mg) after moistening mouth with...” NCT04123899 ↗ “Topical H2RA (2% famotidine solution solved in double-distilled water (containing poloxamer 407, glycerol, lauryl alcohol polyether-4, polyethylene glycol-8, and propylene...” NCT06313307 ↗ “The patients will be randomly assigned to receive either (1) famotidine (40 mg qd) plus thienopyridine used previously or (2) placebo plus thienopyridine treatment alone for 6 months.” NCT02418312 ↗ “Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol” NCT06629337 ↗ “Therefore, this study compared the efficacy and safety of HIP2101 and 20-mg famotidine (RLD2101) in patients with gastric erosions.” PMID 39949051 ↗ Feb 2025 “in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed” NCT04340297 ↗ “Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.” NCT06743243 ↗ “Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis” NCT04990804 ↗ “HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine.” NCT00450658 ↗ “Famotidine 20 mg IV (as a slow push over 2 minutes) administered 3 hours prior to OKN4395” NCT06789172 ↗ “Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks” NCT00613106 ↗ “* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg” NCT01734759 ↗ “1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine” NCT01841489 ↗ “40 mg famotidine every 12 hours for 5 days” NCT04463420 ↗ “famotidine tab 40 mg qd for 6 months.” NCT02551744 ↗ “Group F (famotidine 20 mg)” NCT02703896 ↗ “40 mg Famotidine” NCT05131555 ↗ “famotidine” NCT04990388 ↗ |
| Known as | FAM | “group three received famotidine (FAM) 40 mg p.o. once daily one week before cycle” PMID 33394214 ↗ Jan 20211“Famotidine (FAM)” NCT01232127 ↗ |
| Known as | Pepcid | “Famotidine (Pepcid), a histamine H2 antagonist widely available over-the-counter” NCT04370262 ↗6“Famotidine (Pepcid) will be given at 6 different timepoints:” NCT06706258 ↗ “20mg of oral famotidine (pill) daily Other names: Pepcid” NCT03554291 ↗ “oral famotidine (Pepcid)” NCT06801626 ↗ “Pepcid 40 mg Tablets” NCT01511731 ↗ |
| Known as | Pepcid AC | “This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an...” NCT00557349 ↗1“Pepcid® AC Acid reducer famotidine tablets 20 mg (containing famotidine 20 mg)” NCT01079065 ↗ |
| Known as | Pepcid AC Acid reducer | “Pepcid® AC Acid reducer famotidine tablets 20 mg (containing famotidine 20 mg) distributed by Johnson \& Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034...” NCT01079052 ↗ |
| Known as | RLD2101 | “Therefore, this study compared the efficacy and safety of HIP2101 and 20-mg famotidine (RLD2101) in patients with gastric erosions.” PMID 39949051 ↗ Feb 2025 |
| Action | Inhibit | “blockade of the histamine H2 receptors in the brain” NCT00565175 ↗ |
| Modality | Other / unclassified | “a histamine 2 receptor antagonist (famotidine)” NCT01180179 ↗ |
| Route | Oral | “Oral administration of famotidine by 40mg/day along with lafutidine placebo” NCT00229424 ↗ |
| Target | SELP | “famotidine may prevent vaso-occlusion by decreasing P-selectin expression by endothelial cells.” NCT05084521 ↗ |